While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Older adults who are excessively sleepy at daytime are twice as likely as their non-sleepy counterparts to develop either heart disease, cancer, or diabetes, a new research released at AAN 2020 has shown.
A new combination product (AXS-07), which consists of the triptan rizatriptan and the NSAID* meloxicam, led to rapid and sustained pain relief than treatment with either component alone or placebo in patients with a history of inadequate response to prior acute migraine treatment, according to data from the MOMENTUM study released during the AAN 2020 Meeting.
Treatment with risdiplam helps infants with Type 1 spinal muscular atrophy (SMA) gained significant motor functions, according to the FIREFISH Part 2 pivotal trial presented during the AAN 2020 Meeting.
Patients using the CGRP* blocker fremanezumab for migraine treatment need not worry about cardiovascular (CV) safety of the drug, as pooled data from three phase III trials showed no safety signals for CV events with the treatment, even in those with a CV medical history.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.